NCT02567435: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- State
- Under way
- Phase
- Phase 3
- People
- 325 taking part
- Started
- 1 Jun 2016
- Primary completion
- 30 Jun 2023
- Arms
- Regimen B (VAC/VI/temsirolimus)
- Results
- Posted on the registry
- 5 Oct 2015: Trial registered
- 1 Jun 2016: Trial started
- 1 Oct 2024: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Event-free Survival (EFS)
Primary outcome · Number, Percentage of participants · Up to 3 years from study entry
| Group | Analysed | Value |
|---|---|---|
| Regimen A (VAC/VI) | 148 | 64.80 (95% Confidence Interval 55.5 to 74.1) |
| Regimen B (VAC/VI/Temsirolimus) | 149 | 66.80 (95% Confidence Interval 57.5 to 76.2) |
- p = 0.44, Log Rank (superiority test); 3-Year EFS 65.8. Posted for: Regimen A (VAC/VI), Regimen B (VAC/VI/Temsirolimus)
Overall Survival (OS)
Secondary outcome · Number, Percentage of participants · Up to 3 years from study entry
| Group | Analysed | Value |
|---|---|---|
| Regimen A (VAC/VI) | 148 | 78.70 (95% Confidence Interval 70.9 to 86.4) |
| Regimen B (VAC/VI/Temsirolimus) | 149 | 77.80 (95% Confidence Interval 69.7 to 85.9) |
- p = 0.56, Log Rank (superiority test); 3-Year OS 78.2. Posted for: Regimen A (VAC/VI), Regimen B (VAC/VI/Temsirolimus)